YD Bio Limited (YDESW)Taipei, Taiwan | NasdaqGM
0.66 USD
+0.22
(50.892%)
⇧
(Oct. 14, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 5:37 a.m. EDT
The security is a newly listed instrument with no historical price trajectory to evaluate, rendering any assessment of long-term momentum or structural decline impossible based on past performance. While the balance sheet appears pristine with negligible debt and massive liquidity relative to size, the business is currently unprofitable with negative operating margins and significant cash burn, suggesting the listing is a speculative event rather than a mature investment opportunity. There is no dividend income available to investors. The short-term outlook remains neutral due to the lack of established price history and the absence of a clear post-listing trend, despite the recent news of the business combination. |
| Attribute | Value |
|---|---|
| Debt to Equity Ratio | 0.112 |
| Revenue per Share | 0.018 |
| Beta | -0.16 |
| Profit Margins | 24.67% |
| Previous Name | Breeze Holdings Acquisition Corp. |
| Website | https://www.ydesgroup.com |
| Attribute | Value |
|---|---|
| Address1 | No. 3, Xingnan St. |
| Address2 | 12F. Nangang Dist. |
| Ask | 0.4499 |
| Ask Size | 1 |
| Beta | -0.157 |
| Bid | 0.5493 |
| Bid Size | 1 |
| Book Value | 0.063 |
| City | Taipei |
| Country | Taiwan |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.66 |
| Current Ratio | 5.231 |
| Custom Price Alert Confidence | HIGH |
| Day High | 0.66 |
| Day Low | 0.5636 |
| Debt To Equity | 0.112 |
| Display Name | YD Bio |
| Ebitda | -6,341,945 |
| Ebitda Margins | 0.0 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Two Week High | 0.66 |
| Fifty Two Week High Change | 0.0 |
| Fifty Two Week High Change Percent | 0.0 |
| Fifty Two Week Low | 0.5636 |
| Fifty Two Week Low Change | 0.09640002 |
| Fifty Two Week Low Change Percent | 0.17104334 |
| Fifty Two Week Range | 0.5636 - 0.66 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,784,295,000,000 |
| Float Shares | 16,193,257 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 13 |
| Fullday Change | 0.22260001 |
| Fullday Change Percent | 50.891636 |
| Fullday Price | 0.66 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.29601 |
| Gross Profits | 366,845 |
| Has Pre Post Market Data | 1 |
| Industry | |
| Industry Key | |
| Ipo Expected Date | 2,025-08-29 |
| Language | en-US |
| Long Business Summary | YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, including irritation, foreign body sensation, and eye fatigue; and LSC Eye Drug/Injection, an injectable ophthalmic drug is being developed for the treatment of various retinal and macular disorders, such as age-related macular degeneration, macular edema, choroidal and subretinal neovascularization, and neovascular glaucoma. It also provides Hydrogel (Hioxifilcon A) Soft (Hydrophilic) Contact Lens, a spherical and aspherical lenses. In addition, the company supplies drugs and medical materials for clinical trials; and operates DNA methylation-based oncology testing programs. Further, it provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination, and compliance-focused support for clinical development programs to pharmaceutical and biotechnology companies. It serves corporate and retail customers. The company was founded in 2013 and is based in Taipei, Taiwan. |
| Long Name | YD Bio Limited |
| Market | us_market |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_1898493574 |
| Name Change Date | 2,026-10-15 |
| Net Income To Common | 305,762 |
| Open | 0.5636 |
| Operating Cashflow | -7,256,446 |
| Operating Margins | -3.8212 |
| Phone | 886 2382 0330 |
| Prev Name | Breeze Holdings Acquisition Corp. |
| Previous Close | 0.4374 |
| Price Hint | 4 |
| Price To Book | 10.476191 |
| Profit Margins | 0.24672002 |
| Quick Ratio | 2.699 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.22260001 |
| Regular Market Change Percent | 50.891632 |
| Regular Market Day High | 0.66 |
| Regular Market Day Low | 0.5636 |
| Regular Market Day Range | 0.5636 - 0.66 |
| Regular Market Open | 0.5636 |
| Regular Market Previous Close | 0.4374 |
| Regular Market Price | 0.66 |
| Regular Market Time | 1,792,008,000 |
| Regular Market Volume | 609 |
| Revenue Growth | 3.149 |
| Revenue Per Share | 0.018 |
| Sand P52 Week Change | 0.1570785 |
| Sector | |
| Sector Key | |
| Short Name | YD Bio Limited Warrants |
| Source Interval | 15 |
| Symbol | YDESW |
| Total Cash | 2,662,004 |
| Total Cash Per Share | 0.038 |
| Total Debt | 5,002 |
| Total Revenue | 1,239,311 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Type Disp | Equity |
| Volume | 609 |
| Website | https://www.ydesgroup.com |
| Zip | 115,001 |